FULC Earnings

FULC reported its FY2025Q4 earnings on 2026-03-11, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.31 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following FULC's FY2025Q4 earnings announcement on 2026-03-11, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, FULC's stock price tends to shift by an average of -7.06% in the 10 days leading up to earnings and 2.34% in the 10 days following, providing insight into potential market.

For , analysts estimate FULC's annual revenue to reach , while the EPS is projected at -0.28. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -4.68% over the past three months, indicating analyst expectation in the company's performance.

The correlation between FULC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -4.68%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, FULC's stock price typically moves by -7.06% in the 10 days before its earnings and 2.34% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.28 and revenue of .

The earnings call reveals promising developments in clinical trials, especially for pociredir. Despite some missing data and variability in HbF levels, the robust HbF induction and improvements in biomarkers are encouraging. The company's strategic plan to engage with the FDA and expand the global market is positive. The unmet need in sickle cell disease further supports the potential for pociredir. The management's avoidance of specifics slightly tempers the outlook, but overall, the sentiment is positive due to the promising clinical data and strategic plans.